SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on December 12, 2002; DOI 10.1182/blood-2002-09-2883. This Article Full Text (PDF) All Versions of this Article: 2002-09-2883v1 101/8/3334    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Shimazaki, C. Articles by Nakagawa, M. Search for Related Content PubMed PubMed Citation Articles by Shimazaki, C. Articles by Nakagawa, M. Social Bookmarking                   What's this? Submitted September 24, 2002 Accepted December 2, 2002 Non-T-cell depleted HLA haploidentical stem cell transplantation in advanced hematological malignancies based on the feto-maternal microchimerism Chihiro Shimazaki*, Naoya Ochiai, Ryo Uchida, Akira Okano, Shin-ichi Fuchida, Eishi Ashihara, Tohru Inaba, Naohisa Fujita, Etsuko Maruya, and Masao Nakagawa Second Department of Medicine, kyoto Prefectural University of Medicine, Kyoto, Japan HLA Laboratory, Kyoto, Japan * Corresponding author; email: simazaki{at}koto.kpu-m.ac.jp. Feto-maternal microchimerism suggests that immunological tolerance exists between mother and fetus. Based on this hypothesis, we performed haploidentical stem cell transplantation (SCT) without T-cell depletion (TCD) in five patients with advanced hematological malignancies. HLA incompatibilities for GVHD direction included three loci mismatches in four patients, and two loci mismatches in one patient. Recipient chimeric cells were detected in all patients. The prophylaxis against graft-versus-host disease (GVHD) was tacrolimus with minidose methotrexate. Engraftment was obtained in all patients. An acute GVHD of less than or equal to grade 2 developed in all patients except one who developed tacrolimus encephalopathy. Two patients died; one with fungal pneumonia and the other with disease progression. Three patients survived, with one patient being in complete remission. These observations suggest that haploidentical SCT based on the feto-maternal microchimerism without TCD is possible. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K.-i. Matsuoka, T. Ichinohe, D. Hashimoto, S. Asakura, M. Tanimoto, and T. Teshima Fetal tolerance to maternal antigens improves the outcome of allogeneic bone marrow transplantation by a CD4+CD25+ T-cell-dependent mechanism Blood, January 1, 2006; 107(1): 404 - 409. [Abstract] [Full Text] [PDF] T. Ichinohe, T. Uchiyama, C. Shimazaki, K. Matsuo, S. Tamaki, M. Hino, A. Watanabe, M. Hamaguchi, S. Adachi, H. Gondo, et al. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism Blood, December 1, 2004; 104(12): 3821 - 3828. [Abstract] [Full Text] [PDF] K. M. Adams and J. L. Nelson Microchimerism: An Investigative Frontier in Autoimmunity and Transplantation JAMA, March 3, 2004; 291(9): 1127 - 1131. [Abstract] [Full Text] [PDF] M. Verneris Fetal microchimerism--what our children leave behind Blood, November 15, 2003; 102(10): 3465 - 3466. [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020